Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Trastuzumab deruxtecan |
Synonyms | |
Therapy Description |
Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate (ADC) comprising an anti-ERBB2 (HER2) antibody linked to a derivative of the topoisomerase inhibitor DX-8951, which delivers the cytotoxic agent to ERBB2 (HER2)-expressing tumor cells, potentially resulting in decreased growth of tumors, including tumors with low ERBB2 (HER2) expression (PMID: 27026201). Enhertu (fam-trastuzumab deruxtecan-nxki) is FDA approved for use in patients with ERBB2 (HER2)-positive breast cancer who have received two or more anti-HER2 therapies previously, in patients with ERBB2 (HER2)-low (IHC 1+ or IHC 2+/ISH -) breast cancer received prior chemotherapy, in patients with ERBB2 (HER2)-low or untra-low (IHC 0 with membrane staining) hormone receptor-positive breast cancer who had received endocrine therapy, in patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received prior trastuzumab-based therapy, in patients with non-small cell lung cancer harboring ERBB2 (HER2) activating mutations who have received prior systemic therapy, and in patients with ERBB2 (HER2)-positive (IHC 3+) solid tumors who have received prior systemic therapy (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Trastuzumab deruxtecan | Enhertu | DS-8201|DS8201a|T-DXd|DS-8201|fam-trastuzumab deruxtecan-nxki|DS-8201a | HER2 (ERBB2) Antibody 79 HER2 (ERBB2) Antibody-Drug Conjugate 34 | Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate (ADC) comprising an anti-ERBB2 (HER2) antibody linked to a derivative of the topoisomerase inhibitor DX-8951, which delivers the cytotoxic agent to ERBB2 (HER2)-expressing tumor cells, potentially resulting in decreased growth of tumors, including tumors with low ERBB2 (HER2) expression (PMID: 27026201). Enhertu (fam-trastuzumab deruxtecan-nxki) is FDA approved for use in patients with ERBB2 (HER2)-positive breast cancer who have received two or more anti-HER2 therapies previously, in patients with ERBB2 (HER2)-low (IHC 1+ or IHC 2+/ISH -) breast cancer received prior chemotherapy, in patients with ERBB2 (HER2)-low or untra-low (IHC 0 with membrane staining) hormone receptor-positive breast cancer who had received endocrine therapy, in patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received prior trastuzumab-based therapy, in patients with non-small cell lung cancer harboring ERBB2 (HER2) activating mutations who have received prior systemic therapy, and in patients with ERBB2 (HER2)-positive (IHC 3+) solid tumors who have received prior systemic therapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
No data available in table |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03523585 | Phase III | Trastuzumab deruxtecan Capecitabine + Lapatinib Capecitabine + Trastuzumab | DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | Active, not recruiting | USA | TUR | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | 2 |
NCT03529110 | Phase III | Trastuzumab deruxtecan Ado-trastuzumab emtansine | DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 5 |
NCT03734029 | Phase III | Trastuzumab deruxtecan Nab-paclitaxel Capecitabine Paclitaxel Gemcitabine Eribulin | Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | Active, not recruiting | USA | SWE | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUT | 6 |
NCT04294628 | Phase I | Trastuzumab deruxtecan | Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer | Active, not recruiting | USA | 0 |
NCT04494425 | Phase III | Capecitabine Nab-paclitaxel Trastuzumab deruxtecan Paclitaxel | Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06) | Active, not recruiting | USA | SWE | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
NCT04538742 | Phase Ib/II | Durvalumab + Trastuzumab deruxtecan Pertuzumab + Trastuzumab deruxtecan Durvalumab + Paclitaxel + Trastuzumab deruxtecan Paclitaxel + Trastuzumab deruxtecan Trastuzumab deruxtecan | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (DB-07) | Active, not recruiting | USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 4 |
NCT04622319 | Phase III | Trastuzumab deruxtecan Ado-trastuzumab emtansine | A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) | Active, not recruiting | USA | TUR | ROU | POL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 11 |
NCT04639219 | Phase II | Trastuzumab deruxtecan | A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations (DPT01) | Active, not recruiting | USA | ITA | FRA | ESP | DNK | CAN | BEL | 2 |
NCT04704934 | Phase III | Paclitaxel + Ramucirumab Trastuzumab deruxtecan | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | Active, not recruiting | TUR | ROU | POL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | BRA | BEL | ARG | 10 |
NCT04739761 | Phase III | Trastuzumab deruxtecan | A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer (DESTINY-B12) | Active, not recruiting | USA | SWE | POL | NOR | NLD | ITA | IRL | GBR | FIN | ESP | DNK | DEU | CHE | CAN | BEL | AUS | 2 |
NCT04784715 | Phase III | Pertuzumab + Trastuzumab deruxtecan Docetaxel + Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Trastuzumab deruxtecan | Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | Active, not recruiting | USA | TUR | SWE | ROU | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | ARG | 11 |
NCT05113251 | Phase III | Paclitaxel + Pertuzumab + Trastuzumab + Trastuzumab deruxtecan Trastuzumab deruxtecan Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab | Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | Active, not recruiting | USA | POL | ITA | ESP | DEU | CAN | BRA | BGR | 10 |
NCT05744375 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab (TRANSCENDER) | Active, not recruiting | ESP | 0 |
NCT02564900 | Phase I | Trastuzumab deruxtecan | Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors | Completed | USA | 1 |
NCT03384940 | Phase II | Trastuzumab deruxtecan | DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) | Completed | USA | ITA | GBR | ESP | 1 |
NCT04014075 | Phase II | Trastuzumab deruxtecan | DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02) | Completed | USA | ITA | GBR | ESP | BEL | 0 |
NCT04420598 | Phase II | Trastuzumab deruxtecan | DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease (DEBBRAH) | Completed | ESP | 1 |
NCT04644237 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02) | Completed | USA | NLD | ITA | FRA | ESP | CAN | AUS | 3 |
NCT04744831 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer (DESTINY-CRC02) | Completed | USA | ITA | GBR | FRA | ESP | BEL | AUS | 3 |
NCT04752059 | Phase II | Trastuzumab deruxtecan | Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases (TUXEDO-1) | Completed | AUT | 0 |
NCT06680596 | Phase II | Trastuzumab deruxtecan | Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy (SAFIR3LibHERty) | Not yet recruiting | FRA | 0 |
NCT04379596 | Phase II | Cisplatin + Fluorouracil + Trastuzumab Capecitabine + Oxaliplatin + Trastuzumab Fluorouracil + Oxaliplatin + Trastuzumab Fluorouracil + Trastuzumab deruxtecan Capecitabine + Trastuzumab deruxtecan Durvalumab + Trastuzumab deruxtecan Fluorouracil + Oxaliplatin + Trastuzumab deruxtecan Pembrolizumab + Trastuzumab deruxtecan Capecitabine + Oxaliplatin + Trastuzumab deruxtecan Fluorouracil + Pembrolizumab + Trastuzumab deruxtecan Durvalumab + Fluorouracil + Trastuzumab deruxtecan Capecitabine + Durvalumab + Trastuzumab deruxtecan Capecitabine + Fluorouracil + Pembrolizumab + Trastuzumab deruxtecan Capecitabine + Fluorouracil + MEDI5752 + Trastuzumab deruxtecan Capecitabine + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Cisplatin + Trastuzumab Trastuzumab deruxtecan | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (DG-03) | Recruiting | USA | POL | NLD | ITA | GBR | ESP | DEU | CAN | BRA | 5 |
NCT04482309 | Phase II | Trastuzumab deruxtecan | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) | Recruiting | USA | POL | NLD | ITA | GBR | ESP | CZE | CAN | BRA | BEL | AUS | 6 |
NCT04553770 | Phase II | Trastuzumab deruxtecan Anastrozole + Trastuzumab deruxtecan | Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | Recruiting | USA | 0 |
NCT04686305 | Phase I | AZD2936 + Carboplatin + Trastuzumab deruxtecan AZD2936 + Trastuzumab deruxtecan MEDI5752 + Trastuzumab deruxtecan Trastuzumab deruxtecan Carboplatin + MEDI5752 + Trastuzumab deruxtecan Durvalumab + Pemetrexed Disodium + Trastuzumab deruxtecan Carboplatin + Durvalumab + Trastuzumab deruxtecan Cisplatin + Durvalumab + Trastuzumab deruxtecan | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (DL03) | Recruiting | USA | TUR | POL | NLD | ITA | ISR | FRA | ESP | CAN | BEL | AUS | 6 |
NCT05048797 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan | A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations | Recruiting | USA | TUR | POL | NLD | ITA | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | 7 |
NCT05376878 | FDA approved | Trastuzumab Trastuzumab deruxtecan | An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis | Recruiting | USA | 0 |
NCT05408845 | Phase II | Docetaxel + Trastuzumab Ado-trastuzumab emtansine Trastuzumab deruxtecan | Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers | Recruiting | USA | 0 |
NCT05704829 | Phase II | Trastuzumab deruxtecan | NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (ADAPTHER2-IV) | Recruiting | DEU | 0 |
NCT05845450 | Phase II | Durvalumab Trastuzumab deruxtecan Panitumumab + Sotorasib Vorbipiprant Balstilimab + Botensilimab Nivolumab + Vorbipiprant Panitumumab Botensilimab | Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | Recruiting | ITA | 0 |
NCT05900206 | Phase II | Carboplatin + Docetaxel + Pertuzumab + Trastuzumab Letrozole + Pertuzumab + Ribociclib + Trastuzumab Cyclophosphamide + Epirubicin Trastuzumab deruxtecan Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab | Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer (ARIADNE) | Recruiting | SWE | 0 |
NCT05950945 | Phase III | Trastuzumab deruxtecan | Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | Recruiting | USA | NLD | ITA | IRL | ESP | BRA | BEL | AUS | 2 |
NCT05965479 | Phase II | Trastuzumab deruxtecan | Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer (DECIPHER) | Recruiting | GBR | 0 |
NCT05982678 | Phase II | Trastuzumab deruxtecan | Basket Study for Oligo-metastatic Breast Cancer (ANISE) | Recruiting | NLD | 0 |
NCT06048718 | Phase II | Trastuzumab deruxtecan | T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases (TUXEDO-4) | Recruiting | ESP | AUT | 0 |
NCT06058988 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | Recruiting | USA | 0 |
NCT06172127 | Phase II | Pertuzumab/trastuzumab/hyaluronidase-zzxf Trastuzumab deruxtecan | PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer (DEMETHER) | Recruiting | USA | ITA | ESP | DEU | 0 |
NCT06311214 | Phase II | Trastuzumab deruxtecan Enfortumab vedotin-ejfv Sacituzumab govitecan-hziy | Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) | Recruiting | USA | 0 |
NCT06409390 | Phase I | Fulvestrant + Ribociclib Trastuzumab deruxtecan Sacituzumab govitecan-hziy Capecitabine Abemaciclib + Fulvestrant Cyclophosphamide + Docetaxel + Sargramostim | Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | Recruiting | USA | 0 |
NCT06439693 | Phase II | Docetaxel + Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Trastuzumab deruxtecan Nab-paclitaxel + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab + Tucatinib Ado-trastuzumab emtansine + Tucatinib | The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT06467357 | Phase III | Cisplatin + Durvalumab + Gemcitabine Trastuzumab deruxtecan AZD2936 + Trastuzumab deruxtecan | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer (DESTINY-BTC01) | Recruiting | USA | TUR | SVK | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | 11 |
NCT06486883 | Phase II | Abemaciclib + Fulvestrant Fulvestrant + Palbociclib Exemestane + Ribociclib Anastrozole + Ribociclib Exemestane + Palbociclib Letrozole + Ribociclib Abemaciclib + Exemestane Letrozole + Palbociclib Fulvestrant + Ribociclib Trastuzumab deruxtecan Abemaciclib + Letrozole Anastrozole + Palbociclib Abemaciclib + Anastrozole | Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype (PONTIAC) | Recruiting | ESP | 0 |
NCT06533826 | Phase II | Trastuzumab deruxtecan Datopotamab deruxtecan | TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd (TRADE DXd) | Recruiting | USA | 0 |
NCT06610825 | Phase II | Trastuzumab deruxtecan | Castrate Resistant Prostate Cancer Enhertu Therapy (CaRPET) | Recruiting | USA | 0 |
NCT06643585 | Phase III | Trastuzumab Capecitabine Neratinib Trastuzumab deruxtecan Ado-trastuzumab emtansine Pertuzumab Olaparib | A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse (SURVIVE HERoes) | Recruiting | DEU | 0 |
NCT06750484 | Phase II | Trastuzumab deruxtecan | Trial of Trastuzumab Deruxtecan in Previously Treated HER2 | Recruiting | USA | 0 |
NCT04616560 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma | Suspended | USA | 0 |
NCT03248492 | Phase II | Trastuzumab deruxtecan | A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) | Terminated | USA | ITA | GBR | FRA | ESP | CAN | BEL | 2 |
NCT03505710 | Phase II | Trastuzumab deruxtecan | DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer (DESTINY-Lung01) | Terminated | USA | NLD | FRA | ESP | 1 |
NCT05097599 | Phase II | Binimetinib + Encorafenib Trastuzumab deruxtecan Enfortumab vedotin-ejfv Talazoparib Lorlatinib | Strata PATH (Precision Indications for Approved Therapies) (Strata PATH) | Terminated | USA | 0 |
CKB CORE allows for only a limited number of monthly page views for un-registered users. However, registration is free and allows for unlimited browsing of the CKB CORE content.
You have reached the monthly page view limit. For continued free access to CKB CORE, please register below: